Abstract
Acquisition of resistance to the cytotoxic effects of anticancer agents is one of the most significant impediments to effective cancer therapy. Although various cancer-cell intrinsic mechanisms of drug resistance have been identified, chemotherapy resistance remains one of the major causes of cancer patient death. Emerging evidence suggests that the inflammatory tumor-microenvironment plays an important additional role in modulating drug responsiveness and drug resistance; however, underlying mechanisms are still largely unknown. In this review, we discuss data supporting the idea that crosstalk between components of the immune system and cancer cells can influence chemoresistance, and we will speculate on possible underlying pathways and clinical implications. A deeper understanding of the cancer cell-intrinsic and – extrinsic mechanisms of drug resistance will accelerate the development of novel combinatorial anticancer therapies in which drug resistance is prevented or reversed.
Keywords: Cancer, inflammation, chemoresistance, microenvironment, chemotherapy
Current Pharmaceutical Design
Title: Towards Understanding the Role of Cancer-Associated Inflammation in Chemoresistance
Volume: 15 Issue: 16
Author(s): Karin E. de Visser and Jos Jonkers
Affiliation:
Keywords: Cancer, inflammation, chemoresistance, microenvironment, chemotherapy
Abstract: Acquisition of resistance to the cytotoxic effects of anticancer agents is one of the most significant impediments to effective cancer therapy. Although various cancer-cell intrinsic mechanisms of drug resistance have been identified, chemotherapy resistance remains one of the major causes of cancer patient death. Emerging evidence suggests that the inflammatory tumor-microenvironment plays an important additional role in modulating drug responsiveness and drug resistance; however, underlying mechanisms are still largely unknown. In this review, we discuss data supporting the idea that crosstalk between components of the immune system and cancer cells can influence chemoresistance, and we will speculate on possible underlying pathways and clinical implications. A deeper understanding of the cancer cell-intrinsic and – extrinsic mechanisms of drug resistance will accelerate the development of novel combinatorial anticancer therapies in which drug resistance is prevented or reversed.
Export Options
About this article
Cite this article as:
de Visser E. Karin and Jonkers Jos, Towards Understanding the Role of Cancer-Associated Inflammation in Chemoresistance, Current Pharmaceutical Design 2009; 15 (16) . https://dx.doi.org/10.2174/138161209788453239
DOI https://dx.doi.org/10.2174/138161209788453239 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
microRNAs in Cancer: Lessons from Melanoma
Current Pharmaceutical Design Antifolates - Past, Present and Future
Current Medicinal Chemistry - Anti-Cancer Agents Patents on Immunotoxins and Chimeric Toxins for the Treatment of Cancer
Recent Patents on Drug Delivery & Formulation Prodrugs in Photodynamic Anticancer Therapy
Current Pharmaceutical Design Toxicity of Carbon Nanotubes
Current Drug Metabolism Potentiation of Anti-Cancer Treatment by Modulators of Energy Metabolism
Current Pharmaceutical Biotechnology Prognostic and Therapeutic Implications of MicroRNA in Malignant Pleural Mesothelioma
MicroRNA Liposomes: An Emerging Approach for the Treatment of Cancer
Current Pharmaceutical Design Exosomes and Lung Cancer: Roles in Pathophysiology, Diagnosis and Therapeutic Applications
Current Medicinal Chemistry Design, Synthesis and In-Vitro Cytotoxicity of Novel Platinum (II) Complexes with Phthalate as the Leaving Group
Letters in Drug Design & Discovery New Poly(3-hydroxybutyrate) Microparticles with Paclitaxel Sustained Release for Intraperitoneal Administration
Anti-Cancer Agents in Medicinal Chemistry Systematic Analysis of RNAi Reports Identifies Dismal Commonality at Gene-Level and Reveals an Unprecedented Enrichment in Pooled shRNA Screens
Combinatorial Chemistry & High Throughput Screening Astrocytes: Adhesion Molecules and Immunomodulation
Current Drug Targets Tamoxifen and its New Derivatives in Cancer Research
Recent Patents on Anti-Cancer Drug Discovery Using Pharmacologic Data to Plan Clinical Treatments for Patients with Peritoneal Surface Malignancy
Current Drug Discovery Technologies Inhibition of RET Activated Pathways: Novel Strategies for Therapeutic Intervention in Human Cancers
Current Pharmaceutical Design Drug Targets to Pro-Angiogenetic Factors with Special Reference to Primary Peritoneal Mesothelioma
Endocrine, Metabolic & Immune Disorders - Drug Targets Gene Therapy Approaches for the Selective Killing of Cancer Cells
Current Pharmaceutical Design STING Activation and its Application in Immuno-Oncology
Current Topics in Medicinal Chemistry Comprehensive Review of Cancer Chemopreventive Agents Evaluated in Experimental Carcinogenesis Models and Clinical Trials
Current Medicinal Chemistry